CancerLinQ® Partners with Leading Global Life Sciences Nonprofit

Partnership With Drug Information Association Brings Expanded Biomedical Expertise to CancerLinQ® Initiative

For immediate release
December 12, 2017

ASCO Media Contact:
Kate Crawford
(571) 483-1366
kate.crawford@asco.org

DIA Media Contact:
Michelle Rovner
(215) 483-6122
michelle.rovner@diaglobal.org

ALEXANDRIA, Va. -- CancerLinQ LLC and DIA, (Drug Information Association), a global nonprofit association of health care product development professionals, announced today that they have entered into a programmatic partnership. Under the agreement, DIA will offer the scientific expertise of its members from the life sciences industry to help inform CancerLinQ’s development and rollout. CancerLinQ® is ASCO’s health information technology platform, developed by oncologists for oncologists, aimed at enhancing and improving the understanding and treatment of cancer.

“Since beginning this initiative, the CancerLinQ® team has sought input from experts across the cancer care community,” said CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick. “With DIA, we are broadening the pool of expertise even further. Our collaboration with DIA will provide us with access to unique expertise on the safe and most efficacious use of a rapidly expanding armamentarium of novel anti-cancer agents.”

DIA Associate Director for Scientific Collaborations Tshaka Cunningham, PhD, will serve as DIA representative on the CancerLinQ® Oncology Leadership Council, the strategic advisory body comprised of all official partner organizations that guides the growth and direction of CancerLinQ. DIA will have the ability to access CancerLinQ Discovery™ -- which provides access to curated sets
of statistically de-identified clinical data from the CancerLinQ® platform -- for the association’s internal learning and analysis about the current, real-world state of cancer care.

“We are looking forward to bringing the breadth and depth of knowledge and expertise from our global membership base to the CancerLinQ initiative and being a resource for guiding its growth,” said Sudip Parikh, PhD, Senior Vice President & Managing Director, DIA Americas. “We welcome the opportunity to share our collaborative spirit with the CancerLinQ LLC team and all of its stakeholders in helping cancer care teams to make evidence-based treatment recommendations for their patients.”

The collaboration with DIA is one of many that CancerLinQ LLC has entered into with a coalition of partners and thought leaders, including government agencies, medical specialty societies, and life sciences companies. Since 2016, the American Academy of PAs, American Society of Radiation Oncology, Cancer Informatics for Cancer Centers, College of American Pathologists, Food and Drug Administration, Hematology/Oncology Pharmacy Association, National Cancer Institute, Oncology Nursing Society, and Society of Gynecologic Oncology have joined forces with CancerLinQ LLC. Additionally, in November 2016, AstraZeneca became a founding enterprise partner with CancerLinQ Discovery™. These partnerships offer the CancerLinQ® team guidance and insights that ultimately can contribute to the quality and efficiency of the cancer care delivery system.

CancerLinQ® and CancerLinQ Discovery™ are projects of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit CancerLinQ.org.

###

**About ASCO:**

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.